Core Viewpoint - The article discusses the emergence of Severe Fever with Thrombocytopenia Syndrome (SFTS) caused by the Dabie bandavirus (SFTSV), highlighting its public health challenges and the development of a novel nanobody cocktail for potential treatment [2][8]. Group 1: Disease Overview - SFTS is caused by SFTSV, transmitted by ticks, and has been prevalent in regions such as Anhui, Jiangsu, Zhejiang, and Shandong in China, as well as in Japan and South Korea [2]. - Symptoms include fever and thrombocytopenia, with severe cases leading to multi-organ failure and a mortality rate ranging from 6% to 30% [2]. Group 2: Research Development - A research team led by Professor Wu Xilin from Nanjing University published a study on a cocktail of nanobodies designed to protect against SFTSV in preclinical models [3]. - The study utilized a "sequential heterologous immunization" strategy to isolate and identify nanobodies targeting SFTSV from llamas, leading to the design of a nanobody cocktail (Nb261 + Nb318) [6]. Group 3: Treatment Efficacy - The nanobody cocktail demonstrated complete neutralization of various SFTSV subtypes in vitro and showed excellent therapeutic effects in mouse and aged ferret models, achieving a 100% survival rate, complete viral clearance, and significant improvement in thrombocytopenia and tissue damage [7]. - This research represents the first systematic validation of mixed nanobodies for treating SFTSV in large animal models, providing unprecedented evidence for developing safe and effective SFTSV treatments [8]. Group 4: Future Directions - The research integrates multiple fields, including structural biology, immunology, virology, and translational medicine, showcasing a novel strategy for broad-spectrum antiviral development [9]. - The research team has initiated preclinical studies on pharmacokinetics, toxicology, and process scaling for the Nb261 + Nb318 cocktail, aiming to provide new preventive and therapeutic options for SFTS [9].